ramucirumab + pemetrexed + carboplatin

This is a **combination regimen** comprising ramucirumab, pemetrexed, and carboplatin, primarily studied as first-line therapy for advanced stage IV nonsquamous non-small cell lung cancer (NSCLC). **Ramucirumab** is a fully human monoclonal antibody that targets vascular endothelial growth factor receptor-2 (VEGFR2), inhibiting VEGF-induced angiogenesis. **Pemetrexed** is a multi-targeted antifolate chemotherapy agent that disrupts folate-dependent metabolic processes essential for cell replication. **Carboplatin** is a platinum-based DNA-damaging agent that induces apoptosis. This combination has been investigated in clinical trials, with evidence indicating activity, but it has not demonstrated a statistically significant improvement in progression-free survival compared to pemetrexed plus platinum therapy alone. It is not an FDA-approved or branded combination but is used in clinical studies[1][3][5].